Skip to main content

Table 5 Trial outcomes

From: Remote ischemic preconditioning to reduce contrast-induced acute kidney injury in chronic kidney disease: a randomized controlled trial

 

Control group

n = 66

RIPC group

n = 66

P-value

Primary endpoint

 Increase in cystatin C ≥ 10% after 48–72 h, n (%)

24 (36.4)

24 (36.4)

1

Secondary endpoints

 Contrast-induced acute kidney injury, n (%)

4 (6.1)

2 (3)

0.68

 Serum creatinine after 48–72 h (mg/dL)

1.4 (1.25–1.53)

1.4 (1.2–1.54)

0.92

 Change in serum creatinine after 48–72 h (mg/dL)

−0.11 (−0.3 to 0)

−0.165 (−0.31 to 0)

0.53

 Cystatin C after 48–72 h (mg/L)

1.4 (1.12–1.74)

1.55 (1.22–2)

0.13

 Cystatin C change after 48–72 h

+ 0.065 (− 0.185 to + 0.3)

− 0.01 (− 0.357 to + 0.387)

0.59

Clinical endpoints

 Re-admission within 2 months n (%)

18 (27.3)

16 (24.2)

1

 Dialysis within 2 months n (%)

0

0

n.a.

 Mortality within 2 months n (%)

1 (1.5)

0

0.69

  1. RIPC remote ischemic preconditioning